Getting a pharmaceutical product to market is a complex process and patent rights are key for commercial success

Especially the early stages carry a significant level of financial risk and later on regulatory hurdles make the way to gain commercial success difficult.

Securing patent rights as well as optimising the financial benefits from your innovation through the correct deployment of patent rights is therefore essential.

These are issues which our experts fully understand. Our European Patent Attorneys have decades of experience developing and implementing tailored IP strategies to help ambitious and innovative companies of all sizes achieve commercial success.

Highly qualified scientific thinking and specialised legal expertise help us create strategies that support your commercial objectives.

We have a long history of providing strategic advice, from assisting with developing a business plan through to ensuring your IP portfolios are structured with your commercial goals in mind. These goals can be to attract private or venture capital funding, secure licensing deals, or exit via a sale.

Our track record includes supporting clients preparing for IPO, and we have advised on a number of successful trade sales.

As with all our key industry sectors, aera offers a full range of drafting and prosecution services for patents and registered designs, together with oppositions and appeal procedures.

The strong technical expertise of our pharma team covers all aspects, including:

  • Organic chemistry
  • Pharmaceutical formulation

aera has many direct clients. This inevitably means that we manage and coordinate the prosecution of patent applications all over the world – with the support of our large network of overseas attorneys.

We also prosecute a large number of cases from foreign associates and help securing and defending Scandinavian and European patent rights for international life-science companies, universities, and even governments.



ALL the applicants of a priority application must be named in a subsequent EP application As discussed in a previous post, there were oral proceedings before EPO Board 3.3.08 on 13-17 January 2020 in appeal number T 844/18 in one of the so-called “CRISPR cases”. The written decision, which concluded […]

6. November 2020
by Henrik Skødt
Read more


Patenting of a second (or further) medical use of an already known pharmaceutically active ingredient has been possible at the EPO since decision G 5/83. The Enlarged Board of Appeal introduced the so-called “Swiss type” claims, which have since been replaced by the format of Article 54(5) EPC of the […]

6. October 2020
by Henrik Skødt
Read more


Tuesday this week, it was revealed that Gilead, the producer of Remdesivir, which is currently known as the best drug against COVID-19, had sold nearly almost all of the next three months’ production of its medication to the US health department, leaving the rest of the world without access to buy […]

2. July 2020
by Per Larsen
Read more